Alkermes plc's VIVITROL® Data to be Presented at Upcoming American Psychiatric Association Annual Meeting

Published: May 03, 2012

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that data from several company-sponsored studies of naltrexone for extended-release injectable suspension (XR-NTX) are scheduled to be presented at the 2012 American Psychiatric Association (APA) Annual Meeting in Philadelphia, May 5-9, 2012. XR-NTX is marketed by Alkermes as VIVITROL® and is approved in the U.S. for the treatment of alcohol dependence and opioid dependence, following opioid detoxification.

Back to news